Ferreri, Christopher J. http://orcid.org/0000-0003-2997-4856
Hildebrandt, Michelle A. T.
Hashmi, Hamza
Shune, Leyla O.
McGuirk, Joseph P. http://orcid.org/0000-0002-0539-4796
Sborov, Douglas W.
Wagner, Charlotte B. http://orcid.org/0000-0003-0568-0781
Kocoglu, M. Hakan
Rapoport, Aaron
Atrash, Shebli
Voorhees, Peter M.
Khouri, Jack
Dima, Danai
Afrough, Aimaz
Kaur, Gurbakhash
Anderson, Larry D. Jr. http://orcid.org/0000-0002-6531-9595
Simmons, Gary
Davis, James A. http://orcid.org/0000-0001-7978-1652
Kalariya, Nilesh
Peres, Lauren C. http://orcid.org/0000-0002-6620-8600
Lin, Yi http://orcid.org/0000-0002-1556-6416
Janakiram, Murali
Nadeem, Omar
Alsina, Melissa
Locke, Frederick L.
Sidana, Surbhi http://orcid.org/0000-0003-3288-7614
Hansen, Doris K.
Patel, Krina K. http://orcid.org/0000-0002-8894-027X
Castaneda Puglianini, Omar Alexis http://orcid.org/0000-0003-0423-5870
Article History
Received: 4 May 2023
Revised: 26 June 2023
Accepted: 21 July 2023
First Online: 9 August 2023
Competing interests
: CJF reports payment from participation on an advisory board from Sanofi, and currently holds equity in a publicly-traded company, Affimed. H.H. reports consultancy fees from Sanofi, Janssen, and Bristol Myers Squibb, and payment on speaker bureaus from Sanofi, GSK, and Karyopharm. JPM reports consultancy fees and honoraria from Magenta Therapeutics, Novartis, Bristol Myers Squibb, Juno Therapeutics, Kite, CRISPR Therapeutics, Nektar, and Allovir, reports honoraria from Sana, reports payment on speaker bureaus from Bristol Myers Squibb, Kite, and Allovir, and research funding from Magenta Therapeutics, Juno Therapeutics, Kite, Orca Bio, and Allovir. DWS reports consultancy fees from Sanofi, Bristol Myers Squibb, Janssen, AbbVie, GSK, and Pfizer, and membership on an entity’s Board of Directors or advisory committees for Janssen and GSK. CBW reports that her partner is currently employed at AbbVie. SA reports research funding from Janssen, GSK, and Amgen, honoraria from Sanofi, Takeda, Celgene, and GSK, membership on an entity’s Board of Directors or advisory committees for Janssen, and reports payment on speaker bureaus from Janssen, Sanofi, and GSK. PMV reports consultancy fees from Janssen, Karyopharm, Oncopeptides, AbbVie, Bristol Myers Squibb, Sanofi, GSK, and Pfizer, and involvement on a Data Safety and Monitoring committee for Sanofi. GK reports membership on an entity’s Board of Directors or advisory committees for Bristol Myers Squibb, Cellectar, Sanofi, Janssen, and Arcellx. LDA reports honoraria and membership on an entity’s Board of Directors or advisory committees for Bristol Myers Squibb, Celgene, GSK, AbbVie, Pharmacyclics, Karyopharm, Janssen, Prothena, Sanofi, Beigene, and Amgen. GS reports speaker bureau payment from Kite/Gilead. LCP reports research funding from Bristol Myers Squibb. YL reports consultancy fees from Janssen, Juno, Vineti, Kite/Gilead, Novartis, Legend, Sorrento, Gamida Cell, Celgene, Bluebird Bio, and research funding from Janssen, Kite/Gilead, Merck, Celgene, Bluebird Bio, and Takeda. MJ reports consultancy fees, research funding, and membership on an entity’s Board of Directors or advisory committees from Janssen. ON reports membership on an entity’s Board of Directors or advisory committees from Bristol Myers Squibb, Karyopharm, GPCR Therapeutics, Adaptive Biotechnologies, GSK, and Janssen, and reports research funding from Takeda and Janssen. MA reports honoraria, payment on speaker bureaus, and membership on an entity’s Board of Directors or advisory committees for Bristol Myers Squibb and Janssen, and reports research funding from Bristol Myers Squibb. FLL reports consultancy fees from Takeda, Sana, Daiichi Sankyo, A2, Celgene, Wugen, Umoja, Novartis, Legend Biotech, Kite/Gilead, Janssen, Iovance, GammaDelta Therapeutics, Emerging Therapy Solutions Gerson Lehrman Group, EcoR1, Cowen, Calibr, Cellular Biomedicine Group, Bristol Myers Squibb, Celgene, Bluebird Bio, Allogene, and Amgen, reports research funding from Leukemia and Lymphoma Society, National Cancer Institute, CERo Therapeutics, Bristol Myers Squibb, Novartis, Kite/Gilead, Bluebird Bio, and Allogene, patents and royalties from several patents held by the institution in his name (unlicensed) in the field of cellular immunotherapy, and education or editorial activity from BioPharm Communications, ASH, Aptitude Health, CAREducation, Clinical Care Options Oncology, Imedex, and Society for Immunotherapy of Cancer. S.S. reports consultancy fees from Oncopeptides, Sanofi, Janssen, Magenta Therapeutics, and Bristol Myers Squibb, honoraria from Prothena, and research funding from Janssen, Magenta Therapeutics, Bristol Myers Squibb, and Allogene. DKH reports research funding and membership on an entity’s advisory committee from Bristol Myers Squibb, and reports honoraria from OncLive and Survivorship. KKP reports consultancy fees from Janssen, Celgene, Bristol Myers Squibb, Caribou Sciences, Arcellx, Cellectis, Merck, Pfizer, Karyopharm, and Oncopeptides. OACP reports payment on speaker bureaus from Adaptive Biotechnologies.